ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25aug920

Management of Chronic Obstructive Pulmonary Disease: An Evidence-Based Synthesis of Recent Advances (2018–2025)

Pooja Pandey[1]; Dr. Nitika Thakur[2]*; Dr. Rizu[3]

[1] PhD. Scholar, SSNSR, Sharda University, India
[2,3] Associate Professor, SSNSR, Sharda University, India

Corresponding Author: Dr. Nitika Thakur*

Publication Date: 2025/08/27

Abstract: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide, with over 400 million people affected and more than 3 million deaths annually. Despite therapeutic progress, COPD continues to impose a substantial health and economic burden. This systematic review synthesizes evidence published from 2018–2025 on pharmacological and non-pharmacological management strategies for stable COPD. Using PRISMA methodology, we included randomized controlled trials (RCTs), systematic reviews, and clinical guidelines. Evidence indicates that triple inhaled therapy (ICS/LAMA/LABA) reduces exacerbations and mortality compared to dual therapy, pulmonary rehabilitation improves functional outcomes, and long-term oxygen and non-invasive ventilation (NIV) confer survival benefits in selected patients. Adjunctive measures such as smoking cessation, vaccination, macrolide prophylaxis, and roflumilast also reduce exacerbations in high-risk patients. These findings support a multidimensional approach, integrating pharmacological, rehabilitative, and lifestyle interventions, guided by GOLD 2025 recommendations.

How to Cite: Pooja Pandey; Dr. Nitika Thakur; Dr. Rizu (2025) Management of Chronic Obstructive Pulmonary Disease: An Evidence-Based Synthesis of Recent Advances (2018–2025). *International Journal of Innovative Science and Research Technology*, 10(8), 1316-1319. https://doi.org/10.38124/ijisrt/25aug920

I. INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a major public health challenge and one of the leading causes of morbidity and mortality worldwide. According to the World Health Organization (WHO), COPD currently affects more than 400 million people and accounts for approximately 3.23 million deaths annually, making it the third leading cause of death globally [WHO, 2024]. The disease is characterized by persistent respiratory symptoms and progressive airflow limitation resulting from chronic inflammation of the airways and lung parenchyma, most commonly due to long-term exposure to noxious particles and gases. Cigarette smoking remains the predominant risk factor, although environmental exposures such as indoor biomass fuel combustion, occupational pollutants, and outdoor air pollution are increasingly recognized as major contributors, particularly in low- and middle-income countries (LMICs) [GOLD, 2025].

The pathophysiology of COPD involves complex mechanisms including chronic airway inflammation, structural remodeling, mucus hypersecretion, and loss of elastic recoil due to alveolar destruction. These changes lead to chronic airflow limitation that is not fully reversible. COPD is also frequently associated with systemic manifestations and comorbidities such as cardiovascular disease, diabetes mellitus, osteoporosis, lung cancer, and depression, which significantly worsen prognosis and complicate management [Agustí et al., 2022]. Acute exacerbations—episodes of worsening dyspnea, cough, and sputum production—represent a critical feature of COPD, as they accelerate lung function decline, reduce quality of life, and increase mortality risk [Vogelmeier et al., 2023].

Despite advances in treatment, COPD continues to impose a heavy socioeconomic burden. Patients often experience significant disability, loss of productivity, and impaired health-related quality of life, while healthcare systems face escalating costs due to frequent hospitalizations and long-term treatment needs. The Global Burden of Disease (GBD) study projects that COPD prevalence and mortality will continue to rise, driven by aging populations and persistent exposure to risk factors, particularly in LMICs [GBD 2023]. These trends highlight the urgent need for evidence-based strategies that not only alleviate symptoms but also reduce exacerbations, hospitalizations, and premature mortality.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25aug920

Management of COPD has traditionally focused on pharmacological therapy, primarily bronchodilators and inhaled corticosteroids, aimed at reducing symptoms and preventing exacerbations. However, over the past decade, a paradigm shift has occurred with increasing emphasis on comprehensive, multidimensional care. Non-pharmacological interventions—such as pulmonary rehabilitation, long-term oxygen therapy (LTOT), home non-invasive ventilation (NIV), smoking cessation, vaccination, and lifestyle modifications—have gained recognition as essential components of COPD management. Importantly, recent clinical trials and meta-analyses have refined the role of triple inhaled therapy, roflumilast, and macrolides, while digital health and biomarker-guided approaches are emerging as future directions [Lipson et al., 2018; Rabe et al., 2020; Dretzke et al., 2022].

Despite the growing body of evidence, significant knowledge gaps and practice variations remain. Questions persist regarding the optimal timing and patient selection for triple therapy, the long-term safety of inhaled corticosteroids, the role of oxygen therapy in moderate hypoxemia, and the cost-effectiveness of new technologies. Furthermore, disparities in access to evidence-based interventions continue to undermine outcomes, particularly in resource-limited settings.

Given these challenges, an updated synthesis of recent evidence is warranted. This systematic review aims to critically evaluate and integrate findings from 2018 to 2025 on pharmacological and non-pharmacological management of stable COPD. By consolidating evidence from randomized controlled trials, systematic reviews, and clinical guidelines, this review seeks to provide clinicians, researchers, and policymakers with an updated framework for improving COPD outcomes and guiding future research priorities.

II. METHODS

➢ *Search Strategy*

We searched PubMed, Cochrane Library, NEJM, and WHO databases for studies published between January 2018 and August 2025. Keywords included *COPD, chronic obstructive pulmonary disease, management, pharmacological therapy, non-pharmacological interventions, exacerbation prevention*. Only English-language studies were included.

➢ *Inclusion Criteria (PICOS)*

- Population: Adults diagnosed with COPD
- Intervention: Pharmacological (inhaled therapies, roflumilast, macrolides) or non-pharmacological (pulmonary rehabilitation, oxygen therapy, NIV, smoking cessation, vaccination)
- Comparator: Standard care or placebo
- Outcomes: Exacerbation rate, mortality, quality of life, lung function, hospitalization
- Study Design: RCTs, systematic reviews, clinical practice guidelines

➢ *Data Extraction*

Two reviewers independently extracted data on study characteristics, interventions, and outcomes. Disagreements were resolved by consensus.

III. RESULTS

➢ *Pharmacological Management*

- Triple Inhaled Therapy: The IMPACT [Lipson et al., 2018, NEJM; doi:10.1056/NEJMoa1713901] and ETHOS [Rabe et al., 2020, NEJM; doi:10.1056/NEJMoa1916046] trials demonstrated reduced exacerbations and mortality with triple therapy (ICS/LAMA/LABA) compared with dual bronchodilator therapy.
- Roflumilast: Meta-analyses [Cilli et al., 2019; Garbe et al., 2024] confirmed reduced exacerbations in patients with chronic bronchitis phenotype, though side effects limit use.
- Macrolides: Long-term azithromycin use lowered exacerbation rates [Nakamura et al., 2023; doi:10.1186/s12931-023-02406-4].

➢ *Non-Pharmacological Interventions*

- Pulmonary Rehabilitation: Cochrane reviews [Cox et al., 2021; Zhang et al., 2022] confirmed improvements in exercise tolerance, dyspnea, and quality of life, with telerehabilitation emerging as an effective alternative.
- Long-Term Oxygen Therapy (LTOT): ATS guideline [Jacobs et al., 2020, Am J Respir Crit Care Med; doi:10.1164/rccm.202009-3608ST] recommends ≥15h/day LTOT for severe hypoxemia, improving survival.
- Home Non-Invasive Ventilation (NIV): Meta-analysis [Dretzke et al., 2022, JAMA; doi:10.1001/jama.2019.22343] showed reduced mortality and hospitalization in chronic hypercapnic COPD.

➢ *Preventive Strategies*

- Smoking Cessation: Remains the most effective measure; behavioral interventions and varenicline significantly improve quit rates.
- Vaccination: Influenza and pneumococcal vaccination reduce exacerbations and hospitalizations [WHO, 2024 fact sheet].
- Lifestyle Modifications: Nutritional support and physical activity programs enhance long-term outcomes.

➢ *Guideline Integration*

The GOLD 2025 report [GOLD, 2025] emphasizes individualized treatment, highlighting blood eosinophil counts as a biomarker for ICS use, the role of digital health in monitoring, and expanding rehabilitation access.

IV. DISCUSSION

The management of COPD has undergone substantial transformation in the last decade, driven by new clinical trials, evolving guideline recommendations, and advances in supportive technologies. While pharmacological treatment remains the cornerstone of symptom management and

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25aug920

exacerbation prevention, it is increasingly recognized that a holistic and individualized approach is essential to achieve optimal patient outcomes.

➢ *Pharmacological Therapy: Strengths and Gaps*

Triple inhaled therapy (ICS/LAMA/LABA) has emerged as the most effective pharmacological intervention for reducing exacerbations and mortality among patients with frequent exacerbations. Evidence from the IMPACT and ETHOS trials confirms its superiority to dual bronchodilation. However, controversies persist regarding the risk of pneumonia associated with inhaled corticosteroids, particularly in patients with low eosinophil counts. This has led to the adoption of blood eosinophil levels as a biomarker for tailoring ICS use, marking a shift towards precision medicine in COPD. Yet, accessibility to routine eosinophil testing and interpretation in low-resource settings remains a challenge.

Beyond triple therapy, adjunctive pharmacological options such as roflumilast and long-term macrolide therapy offer benefits for subgroups (e.g., chronic bronchitis phenotype, frequent exacerbators). Nevertheless, their utility is constrained by side effects, antimicrobial resistance concerns, and variable adherence. This emphasizes the need for more targeted trials to refine patient selection criteria and minimize risks.

➢ *Non-Pharmacological Interventions: Core to COPD Care*

The pivotal role of non-pharmacological interventions is now well established. Pulmonary rehabilitation consistently improves exercise tolerance, dyspnea, and quality of life, often achieving benefits comparable to pharmacological therapy. Importantly, the emergence of telehealth-based rehabilitation programs has expanded access, especially during the COVID-19 pandemic, and may help address barriers related to distance, cost, and limited rehabilitation centers. However, the sustainability of benefits remains a concern, as many patients experience a decline in gains after program completion. Integrating ongoing community- or home-based exercise programs may address this limitation.

Long-term oxygen therapy (LTOT) continues to be life-prolonging in patients with severe chronic hypoxemia. Nonetheless, inappropriate prescription in patients with moderate desaturation remains common, despite limited evidence of benefit. The debate over the utility of oxygen in less severe cases highlights the ongoing need for clinician education and stricter adherence to guidelines. Similarly, the role of home non-invasive ventilation (NIV) is expanding, with recent meta-analyses demonstrating improved survival and reduced hospitalizations in chronic hypercapnic COPD. This suggests that NIV should be considered more routinely in advanced cases, although patient adherence and device availability remain significant obstacles.

➢ *Preventive and Supportive Measures*

Preventive strategies remain at the core of COPD care. Smoking cessation is the single most effective intervention for halting disease progression. However, real-world quit rates remain suboptimal, even with pharmacological aids like varenicline and nicotine replacement therapy. Greater investment in behavioral support, digital cessation tools, and policy-level interventions such as tobacco taxation and advertising restrictions is urgently needed.

Vaccination represents another cornerstone of prevention. The integration of annual influenza vaccination, pneumococcal conjugate vaccines, and, more recently, COVID-19 vaccination has been shown to reduce exacerbations and hospital admissions. Expanding coverage in low- and middle-income countries (LMICs), however, remains a challenge due to limited awareness and healthcare infrastructure.

Lifestyle interventions, including nutritional optimization and physical activity promotion, are increasingly recognized as critical but underutilized components of care. Malnutrition and sarcopenia are common in COPD, and targeted nutritional support has demonstrated improvements in outcomes. Multidisciplinary models that combine dietitians, physiotherapists, and respiratory specialists may provide more holistic support.

➢ *Health System and Policy Challenges*

Despite the strong evidence base, real-world implementation of COPD care remains uneven. Adherence to guideline-based treatment is frequently suboptimal, especially in LMICs, where access to inhalers, rehabilitation programs, and diagnostics is limited. Cost remains a major barrier, as advanced inhalers and biologics are unaffordable for many patients. Policymakers must prioritize COPD within non-communicable disease strategies, ensuring equitable access to essential interventions.

Fragmentation of care is another issue. COPD patients often present with multiple comorbidities such as cardiovascular disease, diabetes, and depression, which complicates management. Integrated care models that address multimorbidity are urgently needed. Moreover, the stigma associated with COPD—often linked to smoking—can lead to delayed diagnosis and reduced treatment engagement, further worsening outcomes.

➢ *Emerging Directions and Future Research*

The future of COPD management is likely to be shaped by precision medicine, digital health, and preventive strategies. Biomarker-guided therapy (e.g., eosinophils, imaging phenotypes, genomics) holds promise for individualizing treatment, though evidence is still evolving. Biologic agents targeting type 2 inflammation, already successful in asthma, are under investigation in COPD with high eosinophil counts.

Digital health interventions, including remote monitoring, mobile applications, and artificial intelligence-driven predictive models, are transforming COPD care. Early studies suggest that digital tools can improve self-management, detect exacerbations earlier, and enhance adherence. However, rigorous RCTs are needed to confirm their long-term impact on mortality and healthcare utilization.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25aug920

Finally, greater emphasis on prevention at the population level is essential. Air pollution control, workplace safety measures, and anti-tobacco policies represent upstream strategies that can significantly reduce disease incidence. Research on gene–environment interactions may also provide new insights into susceptibility and open avenues for early intervention.

V. CONCLUSION

Optimal COPD management requires a comprehensive, multimodal approach. Evidence strongly supports triple inhaled therapy, pulmonary rehabilitation, oxygen therapy, and NIV for selected patients, alongside preventive strategies like smoking cessation and vaccination. Future research should explore precision medicine, digital interventions, and health system integration to reduce the global burden.

REFERENCES

[1]. World Health Organization. (2023, March 16). *Chronic obstructive pulmonary disease (COPD) fact sheet*. WHO. World Health Organization
[2]. World Health Organization. (2023, November 15). *Smoking is the leading cause of chronic obstructive pulmonary disease*. WHO. World Health Organization
[3]. Li, X., et al. (2025). Mapping the global distribution, risk factors, and temporal trends of COPD incidence and mortality (1990–2021): Ecological analysis. *BMC Medicine*. BioMed Central
[4]. Lipson, D. A., et al. (2018). Once-daily single-inhaler triple versus dual therapy in patients with COPD. *New England Journal of Medicine*, 378(18), 1671–1680. The New England Journal of Medicine+1
[5]. Rabe, K. F., et al. (2020). Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD (ETHOS trial). *New England Journal of Medicine*, 383(14), e28.
[6]. Lipson, D. A., et al. (2018). Once-daily single-inhaler triple versus dual therapy in COPD. *NEJM*, 378(18), 1671–1680. https://doi.org/10.1056/NEJMoa1713901
[7]. Rabe, K. F., et al. (2020). Triple inhaled therapy at two glucocorticoid doses in COPD. *NEJM*, 383(1), 35–48. https://doi.org/10.1056/NEJMoa1916046
[8]. Jacobs, S. S., et al. (2020). Home oxygen therapy for adults with chronic lung disease. *Am J Respir Crit Care Med*, 202(10), e121–e141. https://doi.org/10.1164/rccm.202009-3608ST
[9]. Dretzke, J., et al. (2022). Home non-invasive ventilation in COPD: A systematic review. *JAMA*, 323(5), 455–465. https://doi.org/10.1001/jama.2019.22343
[10]. Cox, N. S., et al. (2021). Telerehabilitation for chronic respiratory disease. *Cochrane Database of Systematic Reviews*, (1), CD013040. https://doi.org/10.1002/14651858.CD013040.pub2
[11]. Nakamura, K., et al. (2023). Effectiveness and safety of long-term macrolide therapy in COPD. *Respiratory Research*, 24, 240. https://doi.org/10.1186/s12931-023-02406-4
[12]. Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2025). *Global strategy for the diagnosis, management, and prevention of COPD*. Retrieved from https://goldcopd.org